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Abstract 
Novel psychoactive substances (NPS) are increasingly prevalent world-wide although their 
pharmacological characteristics are largely unknown; those with stimulant properties, due to 
interactions with the dopamine transporter (DAT), have addictive potential which their users 
may not realise.  
We evaluated the binding of 1-(1-benzofuran-5-yl)-N-methylpropan-2-amine (5-MAPB) to 
rat striatal DAT by means of quantitative autoradiography with [
125
I]RTI-121, and the effects 
of 5-MAPB on electrically-evoked dopamine efflux by fast-cyclic voltammetry in rat brain 
slices. 5-MAPB displaced [
125
I]RTI-121 in a concentration-dependent manner, with 
significant effects at 10 and 30 µM. The voltammetry data suggest that 5-MAPB reduces the 
rate of dopamine reuptake; while the peak dopamine efflux was not increased, the area under 
the curve was augmented. 5-MAPB can also cause reverse dopamine transport consistent 
with stimulant properties, more similar to amphetamine than cocaine. Molecular modelling 
and docking studies compared the binding site of DAT in complex with 5-MAPB to 
dopamine, amphetamine, 5-APB, MDMA, cocaine and RTI-121. This structural comparison 
reveals a binding mode for 5-MAPB found in the primary binding (S1) site, central to 
transmembrane domains 1, 3, 6 and 8, which overlaps with the binding modes of dopamine, 
cocaine and its analogues. Atomistic molecular dynamics simulations further show that, when 
in complex with 5-MAPB, DAT can exhibit conformational transitions that spontaneously 
isomerize the transporter into inward-facing state, similarly to that observed in dopamine-
bound DAT. 
These novel insights, offered by the combination of computational methods of biophysics 
with neurobiological procedures, provide structural context for NPS at DAT and relate them 
with their functional properties at DAT as the molecular target of stimulants. 
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Introduction 
Among novel psychoactive substances (NPS), benzofurans have a prominent presence in 
Europe and elsewhere. They are phenethylamine derivatives and related to 
methylenedioxyphenethylamines such as 3,4-methylenedioxy-methamphetamine (MDMA, 
Ecstasy) and 3,4-methylenedioxy-amphetamine (MDA), both classified as Class A drugs in 
the U.K. Benzofuran analogues of MDA were first synthesised in the early 1990s (Monte et 
al., 1993) and became prevalent as recreational drugs, also known as ‘legal highs’, nearly two 
decades  later. They were permanently banned as Class B substances in the U.K. in 2014 (The 
Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014, n.d.).  
Benzofurans, similarly to MDA and MDMA, evoke both empathogenic (entactogenic) and 
stimulant effects in users, according to anecdotal reports. While entactogenic properties are 
those which users value for the type of drug-related experience, the stimulant element 
associates with addiction liability that the user may not realise. Stimulant drugs normally 
increase dopamine availability in the brain, including the dorsal and ventral striatum, the 
latter being part of the mesolimbic pathway implicated in the reward-related behaviour (Di 
Chiara and Bassareo, 2007). It has been convincingly demonstrated that dopamine release in 
the nucleus accumbens of this pathway associates with the perception of pleasure and reward; 
it also contributes to the biological underpinnings of drug dependence (Di Chiara and 
Imperato, 1988). The dopamine transporter (DAT) is the molecular target for stimulants, 
responsible for their dopamine-enhancing effects, as originally proposed for cocaine that 
binds at DAT and inhibits dopamine re-uptake thus potentiating dopaminergic 
neurotransmission in mesolimbic/mesocortical pathways (Kuhar et al., 1991). 
We have previously examined a benzofuran, 5-APB (5-(2-aminopropyl)benzofuran, 1-
benzofuran-5-ylpropan-2-amine, benzofury), and found it to bind to the DAT as shown 
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through a displacement of [
125
I]RTI-121 from the DAT in the striatal and cortical areas of rat 
brain, apart from its activity at 5-HT2A receptors (Dawson et al., 2014). 5-APB also caused an 
increase in electrically evoked dopamine efflux, and at high concentrations caused reverse 
transport of dopamine in rat accumbens brain slices (Dawson et al., 2014). Another study 
using cell lines has demonstrated that 5-APB binds to other members of the neurotransmitter: 
sodium symporter (NSS) family of monoamine transporters, with greater affinity at the DAT 
> serotonin transporter (SERT) > norepinephrine transporter (NET) (Iversen et al., 2013). In 
contrast, 5-APB has been found to have a higher preference to the SERT than DAT in human 
embryonic kidney cells (Rickli et al., 2015). The pKi of 5-APB and MDMA at human cloned 
monoamine transporters have been determined: 5-APB: 6.33; 6.30; 5.78, (-)MDMA: 5.50; 
5.21; 5.17, (+)MDMA: 5.70; 5.62; 5.56 for the NET, DAT and SERT respectively (Iversen et 
al., 2013). To our knowledge the pKi for 5-MAPB at monoamine transporters has not yet 
been determined although this drug has been shown to displace monoamine radioligands: at 
10µM 5-MAPB displaced 33% 3H-nisoxetine (NET), 73% 3H-BTCP (DAT) and 75% 3H-
imipramine (SERT) (Shimshoni et al., 2016). 
For the present study, we have chosen 1-(1-benzofuran-5-yl)-N-methylpropan-2-amine (5-
MAPB) which is a N-methylated version of 5-APB, structurally related to MDMA (Welter et 
al., 2015a, 2015b). Online drug user fora suggest that 5-MAPB, despite its illegality, is still 
being used today. Its psychoactive effects include euphoria, visual distortions and reduced 
inhibitions. Inexperienced users appear to feel that 5-MAPB is similar to MDMA, while 
experienced users feel that it is quite unique, with less empathy than one might associate with 
MDMA and reduced sexual dysfunction versus MDMA. Unwanted effects include 
hyperthermia, tachycardia, restlessness, inability to sleep, nystagmus, pupil dilation and jaw 
tension. Some users suggest taking 5-MAPB with a psychedelic dissociative or alcohol to 
enhance the psychoactive effects, or a benzodiazepine to reduce unwanted side-effects and 
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help with sleep (Erowid; Bluelight; The Trip Report). On firmer scientific grounds, the 
National Program on Substance Abuse Deaths (np_SAD report, 2014) in the UK has reported 
nine instances of benzofurans found in post mortem toxicology in the UK in 2012 (the latest 
figures) with benzofurans being cited as the actual cause of death in seven of these cases 
(np_SAD report, 2014). 
 
Here, we aim to assess the stimulant properties of 5-MAPB through in vitro and in silico tests 
that include the evaluation of drug binding to rat striatal DAT by means of quantitative 
autoradiography with [
125
I]RTI-121 as a selective DAT ligand (Hume et al., 1996). We also 
use a functional test measuring electrically evoked dopamine efflux in the nucleus 
accumbens, as the brain region involved in reinforcement and addiction, by means of fast 
cycling voltammetry. We augment our ligand binding and functional data with structural 
results from computational molecular modelling, docking studies and atomistic molecular 
dynamics simulations, which have been previously shown to be robust methods for predicting 
the binding sites of various psychostimulants at human DAT (hDAT) in relation to the 
substrate binding site (Beuming et al., 2008; Bisgaard et al., 2011). We present here, on the 
basis of the crystal structure from Drosophila melanogaster dopamine transporter (dDAT) 
(PDB ID: 4XP1) (Wang et al., 2015), a molecular model of 5-MAPB bound to rat DAT 
(rDAT), in comparison with that of dopamine, amphetamine, 5-APB, MDMA, cocaine and 
RTI-121 also bound to rDAT. Our studies compare the structural changes produced by 
various ligands binding to rDAT to the already ongoing work in hDAT models (Hamilton et 
al., 2013; Hansen et al., 2014; Khelashvili et al., 2015a, 2015b) since it is the primary animal 
model used in functional studies and pre-clinical drug abuse testing.  
We propose here that such a structural analysis is important when creating a stimulant profile 
of NPS as it adds to the insights of binding and functional data derived from the so-far used 
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neurobiological techniques, autoradiography and voltammetry, applied in animal models. It is 
important to understand the molecular determinants of stimulant NPS actions, which may 
underlie their distinct pharmacological effects at DAT.  
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Methods 
2.1 Animals. Eight week old male Wistar rats (Charles River, UK) were kept on a 12/12 h 
light/dark cycle (lights on at 7 AM). Food and water were freely available and rats were 
housed 6 per cage. Temperature and humidity were 18-22°C and 55±15% respectively. Rats 
were treated in accordance with the U.K. Animals (Scientific Procedures) Act 1986 (related 
to the 1986 EU Directive 86/609/EEC) and sacrificed by cervical dislocation with no 
anaesthesia. In the ligand binding studies we used 6 rats. For the voltammetry studies we 
used approximately 20 rats to ensure that each concentration of 5-MAPB was tested in a bran 
slice from a different rat. 
2.2 Chemicals. All chemicals used were supplied by Sigma Chemicals (Poole, UK) except 5-
MAPB which was a gift from John Ramsey (TICTAC Communications Ltd, UK). The 
radioligand for the dopamine transporter, [
125
I]RTI-121 (specific activity  81.4TBq/mmol) 
was purchased from Perkin Elmer (Beaconsfield, U.K.). 
2.3 Radioligand binding study at the dopamine transporter. Brains were removed and 
frozen at -40°C in a mixture of methanol and dry ice, then stored at -80°C. Frozen brains 
were cut into 20 µm coronal sections to harvest the striatum at +1.7mm to -0.3mm versus 
bregma (Paxinos, G Watson, 2007). Serial striatal sections were collected onto polysine-
coated slides and stored at -80
o
C prior to autoradiography. The autoradiography procedure 
was conducted according to Strazielle et al., 1998. After preincubation in 0.05 M NaPB pH 
7.4, sections were incubated with 20 pM [
125
I]RTI-121 in NaPB pH 7.4 with increasing 
concentrations of 5-MAPB (0 - 30 µM) for 60 min at room temperature. Non-specific binding 
was assessed in the presence of 200 µM nomifensine (‘block’ - control). Rinsed and air-dried 
slides were apposed to Kodak BioMax MR films for 3 days; autoradiograms were analysed 
using MCID™, Version 7.0, Imaging Research Inc., Interfocus Ltd, U.K. Flat-field 
correction was applied. The caudate regions of interest were sampled in duplicates for 
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relative optical density; left and right caudate values were averaged and their means were 
calculated to assess the specific binding.  
2.4 Brain slice preparation for functional neurochemistry studies. The brain was removed 
and cut to produce a block containing the accumbens (-5 to +3 mm Vs bregma (Paxinos, G 
Watson, 2007)) which was attached to the chuck of a vibratome, using cyanoacrylate glue, 
then immersed in ice-cold artificial cerebro-spinal fluid (aCSF; pH 7.4). Coronal slices (400 
µm) at the level of the accumbens (+1.0 to +2.2 mm versus bregma) were transferred to a 
slice saver where the slices were immersed in aCSF continuously bubbled with 95% O2/5% 
CO2 at room temperature (22 ± 1°C). After at least 60 min, slices were transferred to the 
brain slice chamber, which was heated by a circulating water bath (Grant, Cambridgeshire, 
UK) and continuously perfused with aCSF (100 ml/h). The temperature in the brain slice 
chamber was 32.5 ± 0.5°C and the slice was equilibrated for 30 min prior to electrical 
stimulation. The composition of aCSF was:  (mM): NaCl (126.0), KCl (2.0), KH2PO4 (1.4), 
MgSO4 (2.0), NaHCO3 (26.0), CaCl2 (2.4), (+)glucose (10.0), bubbled for at least 60 min 
with 95% O2/5% CO2.   
2.5 Fast cyclic voltammetry (FCV). Carbon fibre electrodes were fabricated by sucking a 7 
µm diameter carbon fibre into a 10 cm length borosilicate glass capillary (o.d., 2.0 mm; i.d., 
1.16 mm: Harvard Apparatus LTD, Kent, UK) using a vacuum. This was then pulled to a fine 
tip (Model P-30, Sutter Instruments Co, USA). The carbon fibre protruding from the pulled 
tip was then cut to a length of ~75 µm using a scalpel, under microscopic guidance.  
Triangular voltammetric scans (0 to -1.0 to +1.4 to -1 and back to 0V vs. Ag/AgCl, 480 V/s; 
8 Hz) were applied to the carbon electrode using a Millar Voltammetric Analyser (PD 
Systems, West Molesey, UK), with complete voltammetric scans recorded digitally at 40,000 
Hz (CED1401 Micro3; Spike2 v7.06 software Cambridge Electronic Design, UK). An 
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increase in the current signal at ~600 mV, together with a corresponding reduction peak at -
200 mV, are characteristic of dopamine detection in the accumbens (Robinson et al., 2003). 
See Figure 1. 
[Figure 1 here] 
 
At the start of the 30 min equilibration period, the tip of the carbon electrode was placed into 
the accumbens core, at a depth of approximately 75 µm, using a micromanipulator and under 
microscope guidance. This allowed us to monitor the stability of the brain slice as on some 
occasions (e.g. poor slice health) the slice can release large amounts of dopamine (Davidson 
et al., 2011). A bipolar stimulating electrode, made from 2 stainless steel sharp-tipped 
electrodes (Plastics One, VA USA) was placed about 200 m away from the carbon electrode 
with the tips inserted into the slice to ~100 m using a micromanipulator. Auxiliary (stainless 
steel) and reference (Ag/AgCl) electrodes were placed in 2 corners of the bath. 
2.5.1 Stimulation procedure. We used bipolar electrodes, tips ≈500 µm apart to locally 
stimulate the core of the accumbens. Pseudo-one pulse stimulation (Singer, 1988) was used in 
order to avoid autoreceptor activation, which occurs at about 500 ms after striatal dopamine 
release (Lee et al., 2002; Phillips et al., 2002). The stimulus train was 10 x 1 ms pulses 10 ms 
apart (100 Hz) with a constant current of 10 mA using a Neurolog NL800 stimulus isolator. 
Pulses were programmed using the CED Spike software. 
2.5.2 FCV data analysis. Carbon electrodes were calibrated in 5-10 µM dopamine and the 
brain slice signals were then converted to dopamine concentrations. We measured the area 
under the curve (AUC) of dopamine efflux (Yorgason et al., 2011). We also noted changes in 
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basal levels of dopamine, which would suggest reverse transport of dopamine, as seen with 
amphetamine-like compounds. 
2.6 Homology model of rDAT in complex with dopamine. The construction of the 
homology model of rDAT (rDAT
dDAT
) in complex with dopamine uses established protocols 
previously described for the construction of a human DAT (hDAT) model (Hamilton et al., 
2013; Hansen et al., 2014; Khelashvili et al., 2015a, 2015b). Briefly, as the template, the 
homology model uses the recent crystal structure of the neurotransmitter sodium symporter 
(NSS) DAT from Drosophila melanogaster (dDAT) bound to dopamine (PDB ID: 4XP1) 
(Wang et al., 2015). The model of rDAT
dDAT
 was then prepared with the Protein Preparation 
Wizard of Schrödinger, using a standard protocol with the advanced OPLS3 force field 
implemented in Release 2016-2 (‘Schrödinger, LLC: Portland, OR, 2007, Web address: 
www.schrodinger.com.’, n.d.). Dopamine was then re-docked into this prepared model of 
rDAT
dDAT
 as described earlier (Khelashvili et al., 2015a, 2015b). 
The rDAT
dDAT
 homology model was used in all docking studies after an extensive 
comparison was done to compare the critical transmembrane regions for all fourteen dDAT 
crystal structures. As can be seen from Supplemental Table 1 the Root Mean Square 
Deviation (RMSD) between dDAT crystal structure (PDB ID: 4XP1) and all other thirteen 
dDAT crystal structures (bound to either antidepressants, psychostimulants or mutant dDAT 
bound to psychostimulants) are negligible, especially with a RMSD of <1Å for the critical 
regions of the substrate dopamine binding site and ion binding sites, TMs 1, 6 & 8, which are 
key to the inferences we describe herein. 
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2.7 Binding models of 5-MAPB, amphetamine, 5-APB, MDMA, cocaine and RTI-121. 
The chemical structure of 5-MAPB was built using the LigPrep module of Schrödinger 
Release 2016-2. 5-MAPB was subsequently docked into the rDAT model using the following 
steps implemented in the Induced fit docking (IFD) protocol in the Schrödinger software 
suite: (i) The receptor grid was defined as an enclosing box at the centroid of selected 
residues within 4Å of dopamine; (ii) In the initial Glide docking stage, a soft potential 
docking with van der Waals radii scaling of 0.5 for the protein and ligand was performed 
retaining a maximum number of 20 poses per ligand; (iii) Residues within 7.0 Å of ligand 
poses were kept free to move in the Prime refinement step, and the side chains were further 
optimized; (iv) Poses within 30 kcal/mol of the lowest energy structure obtained in the 
previous step were re-docked using Glide XP; (v) The binding energy (IFDScore) for each 
output pose was computed as implemented in the IFD protocol. This score is the sum of the 
GlideScore from the redocking step and 5% of the Prime energy from the refinement 
calculation. The most favorable binding conformation of the 5-MAPB-rDAT complex (entry 
6 in Supplemental Figure 1SA and 1SC) was selected for analysis, based on the IFDScore 
and visual inspection that coincides with the expectations from the dDAT crystal structures 
with bound dopamine, cocaine and amphetamine and other compounds (Beuming et al., 
2006).  See Supplemental Figure 1S for details. The binding poses for 5-APB and MDMA in 
rDAT
dDAT
 were determined using a similar protocol.  
The chemical structures of cocaine and amphetamine were extracted from the 
crystallographic structures of dDAT (Wang et al., 2015); hydrogen atoms were added and the 
most favorable protonation state was calculated with Protein Preparation Wizard. The cocaine 
scaffold was manipulated in the Build module of Schrödinger Release 2016-2, to add and 
remove atoms to produce RTI-121, followed by the same treatment in the Protein Preparation 
Wizard to calculate the most favorable protonation state. rDAT
dDAT
 complexes bound to 
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cocaine, amphetamine and RTI-121 were prepared using established protocols (Khelashvili et 
al., 2015a, 2015b).  
2.8 Molecular dynamics simulations: The previously well-equilibrated structure of the 
occluded hDAT
dDAT 
model (homology model of the full-length hDAT based on dDAT X-ray 
structure 4M48 with added N- and C-terminal domains) in complex with dopamine and in a 
corresponding membrane environment (Khelashvili et al., 2015b) was used to construct a 
complex of hDAT
dDAT
 bound to 5-MAPB for subsequent atomistic MD simulations. The 
hDAT
dDAT
 protein immersed in the membrane environment, in a box of explicit water, along 
with internal ions and added salts were preserved. The bound dopamine was swapped with 5-
MAPB to create the corresponding complex. To this end, the backbone atoms N, C , C  
and C1 of the benzofuran ring in 5-MAPB structure were aligned on the backbone atoms N, 
C , C  and C1 of the catechol ring of dopamine to overlap the binding position of 5-MAPB 
to dopamine in hDAT
dDAT
.  After a short (0.5ns) equilibration, this new system was subjected 
to unbiased MD simulations totalling ~250ns. The simulations were carried out as described 
in (Khelashvili et al., 2015b) using ACEMD software (Harvey et al., 2009). Briefly, the 
simulations employed the all-atom CHARMM27 force field for proteins with CMAP 
corrections was used (Brooks et al., 2009) as well as the CHARMM36 force field for lipids 
(Klauda et al., 2010), the TIP3P water model, and the CHARMM-compatible force-field 
parameter set for PIP2 lipids (Lupyan et al., 2010). The PME method for electrostatic 
calculations was used, along with 4fs integration time-step with standard mass repartitioning 
procedure for hydrogen atoms implemented in ACEMD. More details about the 
computational protocol can be found in (Khelashvili et al., 2015b). 
The trajectory was analysed with VMD (Humphrey et al., 1996) and various analyses 
tools developed in-house.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
14 
 
 
2.9 Statistics.  For the binding study we analysed the data with a 1-way ANOVA. For the 
voltammetry study statistical analyses were performed on peak effects of each drug 
concentration on each brain slice, which was typically found around 45-50 min after drug 
application. Statistical analysis was carried out using SigmaPlot (v. 11.0).  We used a 1-way 
ANOVA (independent variable = concentration) with post-hoc Tukey’s. In all graphs data are 
presented as means ± SEMs and significance is set at p < 0.05.  
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Results 
Ligand Binding. 5-MAPB caused a concentration dependent displacement of [
125
I]RTI-121 
from the DAT (F(4, 29) = 13.55, p < 0.001). Post hoc analysis with Dunnett’s methods 
revealed that both 10 and 30 µM 5-MAPB caused a significant reduction, by 30% and 50% 
respectively, in [
125
I]RTI-121 binding versus the control (p < 0.05; Figure 2A-C); the 
cocaine/[
125
I]RTI-121 displacement curve shown for comparison (Figure 2D).  
[Figure 2 here] 
Fast cyclic voltammetry in accumbens slices.   
There was evidence of reverse transport where application of 5-MAPB caused an increase in 
background dopamine levels independent of electrical stimulation. This was seen with 5-
MAPB at both 1 and 10 µM, although did not happen on every occasion (see Figure 3). 5-
MAPB also had an effect on electrically evoked dopamine efflux (H(3) = 8.823, p < 0.05), 
post hoc analysis revealed that both 0.1 and 10 µM 5-MAPB increased the AUC (Figure 4). 
We have previously shown that more classical DAT blockers such as cocaine diethylpropion 
and bupropion do not increase basal levels of dopamine, in contrast to amphetamine (Opacka-
Juffry et al., 2014). 
[Figures 3 and 4 here] 
Molecular modelling and docking of ligands. We built the molecular models for the 
binding of 5-MAPB, dopamine, amphetamine, 5-APB, MDMA, cocaine and RTI-121 in 
Rattus norvegicus dopamine transporter (rDAT) (Figure 5A and Supplemental Figure 2SA). 
These models were based on the high-resolution structure of the Drosophila melanogaster 
dopamine transporter, dDAT, bound to the neurotransmitter dopamine (PDB ID: 4XP1) 
(Wang et al., 2015) and a refined structure-based sequence alignment of neurotransmitter 
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sodium symporter (NSS) proteins (Beuming et al., 2006). The docking results confirmed that 
the 5-MAPB pose overlaps with the dopamine, amphetamine, 5-APB, MDMA, cocaine and 
RTI-121 binding sites (Supplemental Figure 2SB). Indeed, comparison of molecular models 
of dopamine (Figure 5B), amphetamine (Figure 5C), 5-APB (Figure 5D), MDMA (Figure 
5E), 5-MAPB (after an induced-fit protocol, that allows backbone flexibility, Figure 5F), 
cocaine (Supplemental Figure 2SC) and RTI-121 (Supplemental Figure 2SD) show that these 
compounds share a binding site at the centre of rDAT and located in a position corresponding 
to the primary substrate-binding site cavity (S1) seen in previous modelling studies in hDAT 
(Beuming et al., 2008; Bisgaard et al., 2011). Specifically, in rDAT, aromatic-aromatic 
stacking interactions are observed between Tyr156 and the catechol ring of dopamine, phenyl 
ring of amphetamine and the fused benzene and furan rings of 5-APB, 5-MAPB and MDMA. 
According to our initial models when dopamine (Figure 5B), amphetamine (Figure 5C), 5-
APB (Figure 5D), MDMA (Figure 5E), cocaine (Figure 2SC) and RTI-121 (Figure 2SD) are 
bound to rDAT
dDAT
 they do not disrupt the stabilizing hydrogen bond between Asp79 and 
Tyr156 shown to be important in stabilizing the S1 binding pocket (Beuming et al., 2008). 
The dock of 5-MAPB (Figure 5F) also suggests a hydrogen bond between the OH group of 
Tyr156 and Asp79 as well as a stabilising salt bridge between Asp79 and the protonated 
amine of 5-MAPB (Figure 5F), this similar motif has been described previously for 
dopamine, amphetamine and MDMA binding to hDAT (Beuming et al., 2008).  These 
observations are similar to those reported from the recent dDAT crystal structures (Wang et 
al., 2015). In fact all reported poses of these docked compounds preserve ~3Å-4Å separation 
between Y156 and D79. 
These findings are interesting, especially for the larger compounds, cocaine and RTI-121, 
when compared to previous modelling studies and the recent crystallographic data. A 
previous work (Beuming et al., Nature 2008) on a homology model of human DAT based on 
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LeuT (Leucine transporter, bacterial homologue of NSS) bound to various small molecules 
including dopamine, amphetamine, benzotropine, the benzotropine analog JHW007, MDMA, 
cocaine, CFT explored the time-dependent behaviour of the Tyr-Asp hydrogen bond with 
molecular dynamics (MD) simulations. These studies concluded that larger molecules such as 
CFT and cocaine disrupt the Y156-D79 hydrogen bond; a finding that was supported by 
mutagenesis studies where dopamine uptake was markedly decreased because of the 
destabilization of the dopamine-binding pocket. In contrast, the paper by Wang et al., Nature 
2015; captures structures of Drosophila Melongaster bound to cocaine, β-CFT and RTI-55 in 
an outward-open conformation and where the Asp46-Tyr124 (dDAT numbering) interaction 
is not disrupted similar to our initial docks. It is important to note, as mentioned above, that  
the previous model of hDAT was based on a template of LeuT (Beuming et al., 2008) while 
our current model of rDAT is based on dDAT, and includes both N- and C-terminal regions, 
constructed from a previous protocol developed for hDAT (Khelashvili et al., 2015a).  
While reconciliation of structural differences between different sized compounds are outside 
the context and scope of the current manuscript, we probed with atomistic MD simulations 
structural and dynamics characteristic of hDAT bound to 5-MAPB. Human DAT was chosen 
in order to facilitate comparison of the computational results with previous large-scale MD 
simulations of dopamine-bound hDAT (Khelashvili et al, 2015b). Thus, we have reported on 
spontaneous occluded-to-inward-facing transitions in hDAT and concomitant release of Na+ 
ion from the functional Na2 site (Na2 ion) induced by PIP2 lipid-mediated interactions 
between the N-terminal domain and the intracellular loop 4 (IL4) of hDAT.  Here, starting 
with the occluded model of hDAT (with Na+ and Cl- ions in their respective binding sites) 
but with substituting dopamine in the S1 site with 5-MAPB (see Methods), we observed 
similar destabilization of the Na2 ion (Figure 6A) and isomerization to the inward-facing 
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state (as monitored by the disruption of the intracellular network of ionic interactions 
including R60-D436 and Y335-R428, Figure 6B) during ~250ns atomistic MD simulations.  
Interestingly, we find that the Y156-D79 minimum distance is maintained at ~4Å throughout 
the trajectory decreasing to even smaller (~2Å) distances towards the end of the simulation 
(Figure 6A) suggesting that Y156-D79 interaction is preserved in the presence of 5-MAPB.  
These computational studies highlight that when in complex with 5-MAPB, DAT can exhibit 
conformational dynamics that lead to spontaneous isomerization of the transporter into 
inward-facing state, similarly to that observed in dopamine-bound DAT (Khelashvili et al, 
2015b). 
Figure 5 and Figure 6 here 
Discussion 
We characterised a stimulant profile of an exemplar benzofuran NPS by means of a set of 
methods, that included not only the previously used neurobiological approaches, 
autoradiography and in vitro fast cyclic voltammetry, but also a biophysical method of 
molecular modelling of interactions between ligands and their biological targets. 
We chose 5-MAPB as an example of NPS and yet nearly unknown for its pharmacological 
properties (Welter-Luedeke and Maurer, 2015). There are no previous studies of the 
pharmacology of 5-MAPB, but user reports suggest that this benzofuran is a stimulant and 
empathogen/entactogen, as well as having some hallucinogenic properties.  The benzofurans 
were initially marketed as a legal form of MDMA (Ecstasy); the UK Advisory Council on the 
Misuse of Drugs (ACMD) considers 5-MAPB to be structurally closer to MDMA (See Figure 
5A) than 5-APB, see also (Welter et al., 2015a, 2015b). We have previously examined the 
neuropharmacology of 5-APB and shown that it displaces RTI-121 from the DAT and 
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ketanserin from the 5-HT2A receptor; it also causes a prolongation of electrically evoked 
dopamine (Dawson et al., 2014).  
The present data demonstrate that 5-MAPB binds to the DAT in rat brain tissue, where it 
competes at the transporter with the selective DAT ligand, [
125
I]RTI-121, in a concentration-
dependent manner, but being less potent than cocaine. In that it resembles 5-APB (Dawson et 
al., 2014). The autoradiography analysis, while of high anatomical resolution and fully 
quantitative to assess ligand competition in bran tissue in vitro, does not inform about the 
very mechanism of interaction between the drug tested and the DAT, in particular it does not 
distinguish whether the drug competitively blocks the DAT and therefore reduces dopamine 
reuptake, largely like cocaine e.g. (Jones et al., 1995) or whether the drug interacts with DAT 
to enter the presynaptic compartment where it displaces newly synthesised dopamine the way 
amphetamine does (Butcher et al., 1988).  
 
In this respect, the functional voltammetry approach complements the binding study as it can 
distinguish between the states of dopamine reuptake inhibition versus enhanced dopamine 
release. It achieves that through the real time (sub-second) analysis of dopamine efflux 
following electrical stimulation before-and-after a drug application, as we have demonstrated 
for a range of cathinones (Opacka-Juffry et al., 2014). The present study revealed that 5-
MAPB can cause reverse transport and also increases the AUC of electrically evoked 
dopamine efflux. These data are consistent with 5-MAPB having a stimulant profile.  
Interactions between stimulant NPS and DAT may be even more complex as there is 
evidence that cocaine, formerly seen as a classical DAT blocker, can not only block 
dopamine reuptake but also amplify dopamine release by mobilizing a reserve pool of 
dopamine-containing synaptic vesicles (Venton et al., 2006). The intricate mechanisms of 
stimulant-DAT interactions, which lead to augmentation of dopamine neurotransmission, 
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should be investigated and understood in the future as they are important for the 
psychostimulant effects and addictive potential of drugs including NPS. Such studies of 
molecular interactions are theoretically achievable by means of biophysical methods of 
molecular modelling; our present approach is a stepping stone in that direction.  
 
The present molecular modelling and docking studies reveal a binding mode for 5-MAPB 
that is found central to the transmembrane domains 1, 3, 6 and 8, which overlaps extensively 
with that of dopamine, amphetamine, 5-APB, MDMA, cocaine and its analogues. We 
observe the conservation of the Tyr156-Asp79 hydrogen bond when dopamine, 
amphetamine, 5-MAPB, 5-APB, MDMA, cocaine and RTI-121 are docked to the rDAT
dDAT
 
model. Although the present dock of 5-MAPB suggests a hydrogen bond between Tyr156 
and Asp79 similar to dopamine, amphetamine, 5-APB, MDMA, cocaine and RTI-121 seen 
from the recent crystal structure of dDAT (Wang et al., 2015), the stability and time-
dependent behaviour of these interactions need to be quantitatively investigated with 
molecular dynamics simulations to explain the differences seen between the previous models 
based on LeuT (Beuming et al., 2008) and the recent crystal structures (Wang et al., 2015). 
Atomistic MD simulations performed here to investigate the conformational dynamics in 
DAT when complexed with 5-MAPB revealed the spontaneous release of Na+ ion from the 
Na2 site as well as disruption of the intracellular network of ionic interactions that stabilize 
DAT in the inward-closed state (Kniazeff et al., 2008) suggesting that the 5-MAPB-bound 
transporter exhibits conformational changes that are consistent with the early stages of inward 
opening, as observed for dopamine-bound DAT (Khelashvili et al, 2015b).  
Longer simulations are needed to observe the effect of different sized ligands on the 
structural rearrangements of the binding site residues, such as investigating the occurrence of 
the stabilising interactions of the OH group of Tyr156 and Asp79 and the salt bridge between 
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Asp79 and the protonated amine of 5-MAPB and binding affinity for structurally similar 
compounds that may differ in functional groups or moieties. Free-energy calculations can be 
further implemented to address these questions after a thorough understanding of the 
dynamics of the system gathered from sufficiently long unbiased molecular dynamics. 
Conformational changes emerging over long-scale simulations can indicate the structural and 
dynamic elements of the mechanisms governing the interactions of 5-MAPB with DAT. This 
work is ongoing but inferences can then be probed using comparisons among various 
structural families of ligands, which are expected to elicit structure-related structural and 
dynamic consequences of binding. 
A mechanistic characterization of these changes in rat DAT is of direct relevance as this is 
the primary animal model used in functional studies and pre-clinical drug testing. A structural 
comparison is needed to determine the relevance of binding affinity data from rat models 
used in translational studies that ultimately inform decisions on drug classification. In this 
respect, it is important to establish if functional phenotypes of 5-MAPB and amphetamine 
can be explained by common mechanisms. Indeed, extensive studies of amphetamine-
induced and DAT-mediated efflux of dopamine have established that the efflux process 
requires activation of specific molecular machinery in the cell that includes various kinases, 
scaffolding proteins, and even specific lipid membrane components acting on DAT 
(Khelashvili et al., 2015b; Khelashvili and Weinstein, 2015).  It, therefore, remains to be seen 
whether 5-MAPB-induced dopamine efflux as well is dependent on activation of similar 
molecular machinery.  
We are further developing molecular modelling approaches to study NPS stimulant effects, 
with dynamic analysis of various compounds and their analogues interacting with the 
monoamine transporters. With the determination of the new crystal structure of hSERT 
(Coleman et al., 2016),  investigations of a large repertoire of stimulant compounds bound to 
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hSERT, hDAT and hNET could provide a pharmacological characterisation of selectivity 
when combined with functional studies. Such novel molecular-computational approaches, 
working in concert with traditional functional studies to define the stimulant properties of 
NPS and effectively their addictive potential, are advantageous and should become 
increasingly applicable in the future.  
The present data provide the first pharmacological and structural evidence of 5-MAPB’s 
stimulant mechanism of action, and suggest potential addictive properties, which informs 
about the health risk related to its use. The present study demonstrates the benefits of 
combining computational methods of biophysics with neurobiological procedures by 
providing novel insights into the structural determinants of NPS at the dopamine transporter 
and subsequently reconciling them with their functional properties at DAT as the main 
molecular target of stimulant drugs of addiction.  
Conclusions 
We have found 5-MAPB to bind to the DAT and displace RTI-121 as DAT ligand, and to 
slow down reuptake of electrically evoked dopamine in the rat accumbens. In addition 5-
MAPB can cause reverse transport of dopamine, which is a feature of amphetamine–like 
substances.    
Molecular modelling has demonstrated a binding mode for 5-MAPB at DAT that occupies a 
binding pocket that is deeply buried in the transporter protein structure and overlaps with the 
binding site of the substrate dopamine and other stimulants such as amphetamine, MDMA, 5-
APB, cocaine and RTI-121. Atomistic simulations indicate a number of structural 
rearrangements that stabilise the inward facing conformation of DAT when bound to 5-
MAPB, such as the spontaneous release of Na2 and the rearrangement of the intracellular 
gates.  These findings support the functional neurochemistry findings of the initial transport 
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steps and longer atomistic simulations are needed to resolve whether the stimulant behaves 
like amphetamine.  
The present data, by combining computational methods of biophysics with neurobiological 
procedures, provide the first structural and pharmacological evidence of 5-MAPB’s stimulant 
mechanism of action, and suggest its potential addictive properties, which informs about the 
health risk related to its use. Such approaches can be applied to assess addictive potential of 
other NPS. 
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Figure 1. Methods for voltammetry showing 5-MAPB causes reverse transport of 
dopamine. A: input voltage waveform applied to the carbon fibre electrode (0 to -1 to +1.4 to 
-1 and back to 0 V at 480V/s). B: resultant charging current at the carbon fibre electrode. C: if 
one takes the electrode current in the presence of dopamine and subtracts the signal in the 
absence of dopamine one should be left with only a Faradaic current from the oxidation and 
reduction of dopamine. Here we see an oxidation peak at ~600 mV and a reduction peak at -
200 mV, exactly where one would expect to see peaks if dopamine was present. The data 
from ‘C’ are taken from Figure 3B and the signal at ‘Y’ is subtracted from the signal at ‘X’. 
These data show that 5-MAPB can cause reverse transport of dopamine. 
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Figure 2. Displacement of [125I]RTI-121 by 5-MAPB in rat caudate sections. 5-MAPB 
displaced [125I]RTI-121-in a concentration dependent manner; (A) total [125I]RTI-121 
binding; binding of [125I]RTI-121 in the presence of (B) 10 μM 5-MAPB and (C) 30 μM 5-
MAPB; (D) combined concentration response curve for displacement of [125I] RTI21 
binding by 5-MAPB, data for cocaine are derived from Opacka-Juffry et al., (2014) and given 
for comparison (dashed-line). Values are means ± SEM. *P < 0.05 versus control (0 μM), 
n=6 per drug concentration. 
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Figure 3. Dopamine efflux measured from the accumbens core. A. shows a typical 
experiment where we stimulate (10 pulses at 100 Hz, upward arrows) every 5 min to evoke 
dopamine release. 5-MAPB 10 μM is added at the downward arrow. One can see that the 
peak height of evoked dopamine does not increase, but towards the end of the experiment the 
dopamine efflux event gets longer suggesting that the DAT is blocked. B. is essentially the 
same experiment as ‘A’ except that on this occasion when 5-MAPB, again at 10 μM, is 
added, one sees a large increase in the background signal, similar to what one might see with 
amphetamine. When the signal was electrochemically analysed one could see that the 
increase was due to dopamine (see Figure 1C). Note that the data on the upper panel are on a 
different vertical scale to the lower panel, by a factor of 10.  
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Figure 4. Effect of 5-MAPB on electrically evoked dopamine efflux. Left panels show raw 
data before (far left) and 50-60 min after (middle) 5-MAPB application. The upward arrow 
shows where electrical stimulation (10 pulses at 100 Hz) took place. Note that peak dopamine 
efflux does not increase but reuptake is slowed after 5-MAPB. Right panel: concentration 
response curve showing that 5-MAPB at 0.1 and 10 μM increase AUC dopamine efflux. *p < 
0.05. Values are means ± SEM, n = 4-6. 
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Figure 5. Molecular models of rDAT and ligands. (A) Structure of dopamine, 
amphetamine, 5-MAPB, MDMA and 5-APB. The represented poses as well as selected 
binding site residues are depicted individually in panels B to F. Molecular docking models of 
(B) dopamine, (C) amphetamine, (D) 5-APB (E) MDMA and (F) 5-MAPB (See 
Supplemental Figure 1S for details of docking pose). Each of these distinct ligands occupies a 
binding pocket that is deeply buried in the transporter structure and overlaps with the binding 
site of the substrate dopamine. Selected central binding site residues from each ligand are 
shown in yellow and labelled respectively. 
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Figure 6. Spontaneous release of the Na+ ion from the Na2 site in the 5-MAPB bound to 
hDAT
dDAT
 (in white rendering) simulation. (A) Time-evolution, during the hDAT
dDAT
 run, 
of minimum distances between Y156 and D79 (purple) and between the two Na+ ions 
initially in the Na1 and Na2 sites (red). (B) The positions of the ions and the ligand and 
relevant TM regions of hDAT
dDAT
 are taken from the initial conformation of the system. The 
rearrangement of the various residues of the intracellular gates: R60, D436, E428 and Y335 
and the residues coordinating Na2: L418, D421, G75 and V78 are rendered in licorice at 
intervals of 40 timesteps. Na2 is rendered in van der waals and its displacement from the Na2 
site is represented also at intervals of 40 timesteps. Na1 and Cl ions are coloured in blue and 
pink, respectively, for clarity. The snapshots are related to each other by 180o rotation around 
the vertical axis (direction perpendicular to the membrane plane). 
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Highlights 
Neurobiological and molecular modelling analyses indicate that 5-MAPB 5-MAPB binds to 
the dopamine transporter (DAT) and displaces RTI-121 as DAT ligand in rat brain tissue. 
5-MAPB slows down reuptake of electrically-evoked dopamine in the rat accumbens and 
causes reverse transport of dopamine, which is a feature of amphetamine–like substances.    
Molecular dynamics simulations describe the interactions between 5-MAPB and DAT. These 
approaches can be used for other NPS when assessing their functional properties at DAT as 
the molecular target of stimulants. 
